This research matters to people with type 2 diabetes who are at high risk for heart problems but do not yet have known significant atherosclerosis. Many such patients take statins to lower cholesterol, and this study looked at adding another drug, evolocumab, to see if it could further reduce their risk of major heart events.
The researchers conducted a phase 3 randomized controlled trial across 774 sites in 33 countries. They enrolled 3,655 patients with diabetes, no prior heart attack or stroke, and LDL cholesterol levels of 90 mg/dL or higher. Half received evolocumab 140 mg every two weeks by injection, added to their existing statin therapy, while the other half received a matching placebo added to their statin. The study followed participants for a median of 4.8 years.
The main findings showed that evolocumab reduced the risk of major cardiovascular events. For the combined outcome of coronary heart disease death, heart attack, or ischemic stroke, events occurred in 5.0% of the evolocumab group versus 7.1% of the placebo group, a hazard ratio of 0.69, meaning about a 31% relative reduction. The absolute difference was 2.1%. When the analysis included also ischemia-driven arterial revascularization, events occurred in 7.6% versus 10.5%, a similar 31% relative reduction with an absolute difference of 2.9%. All-cause death also showed a reduction, with 7.8% in the evolocumab group versus 10.1% in the placebo group, a hazard ratio of 0.76.
The study did not report specific safety data, adverse events, serious events, or discontinuations in the provided information. The main limitation is that this is a prespecified subgroup analysis of a larger trial, not the primary analysis, so the results apply specifically to patients without known significant atherosclerosis and with diabetes. The findings support a link between adding evolocumab to statins and lower event rates in this group, but they do not prove cause and effect for all patients.
For patients right now, this means that for high-risk diabetes patients without known heart disease, adding evolocumab to a statin may lower the chance of heart attacks, strokes, and death. However, people should not change treatment based on this single subgroup analysis. Discussing options with a healthcare provider is essential, as decisions depend on individual health, other conditions, and current guidelines.